Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10768177 | 0.83 | PKM (0.78) | PTK2PKMLMNANOTUMGAA | |
| SCHEMBL10311035 | 0.81 | PKM (0.63) | PTK2PKMLMNANOTUMGAA | |
| SCHEMBL28234257 | 0.81 | NOTUM (0.63) | PTK2PKMLMNANOTUMGAA | |
| SCHEMBL29808183 | 0.79 | MEN1 (0.58) | PTK2PKMLMNANOTUMGAA | |
| SCHEMBL27994854 | 0.79 | MEN1 (0.58) | PTK2PKMLMNANOTUMGAA | |
| SCHEMBL14050049 | 0.78 | HTT (0.75) | PTK2PKMLMNANPC1KDM4E | |
| SCHEMBL3635051 | 0.78 | PKM (0.64) | PTK2PKMLMNANOTUMGAA | |
| SCHEMBL19219054 | 0.78 | PTK2 (0.91) | PTK2PKMLMNANOTUMGAA | |
| SCHEMBL3183163 | 0.77 | PTK2 (1.00) | PTK2PKMLMNANOTUMGAA | |
| SCHEMBL24637025 | 0.77 | NOTUM (0.49) | PTK2PKMLMNANOTUMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-108558785-B | 5-aryl-2-arylseleno-1, 3-oxazole compound and preparation method thereof | 温州医科大学 | 2021-06-15 | — | — | CN | disclosed |
| EP-2714667-B1 | AMINOOXAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | DESAI LAXMAN S (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-2714667-B1 | AMINOOXAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | DESAI LAXMAN S (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-2838883-B1 | NEW PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-11-08 | — | — | EP | disclosed |
| US-9187429-B2 | Phenyl-tetrahydroisoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2838883-A1 | NEW PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8865709-B2 | Aminooxazole inhibitors of cyclin dependent kinases | Neosome Life Sciences, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865709-B2 | Aminooxazole inhibitors of cyclin dependent kinases | Neosome Life Sciences, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120302578-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | Neosome Life Sciences, LLC (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302578-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | Neosome Life Sciences, LLC (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302578-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | Neosome Life Sciences, LLC (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2412372-A1 | 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7998993-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2220059-B1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LAB (US) | 2011-08-03 | — | — | EP | disclosed |
| CN-101835762-A | 2-aminooxazole derivatives as TRPV antagonists useful for the treatment of pain | ABBOTT LAB | 2010-09-15 | — | — | CN | disclosed |
| EP-2220059-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055749-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302578-A1 | Aminooxazole Inhibitors of Cyclin Dependent Kinases | CDK1, CCNK, CCNI | PTK2 123/4885PKM 1227/4885LMNA 3488/4885 |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV2, TRPV3 | PTK2 3270/4885PKM 2086/4885LMNA 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.